Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11505600

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11505604

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11505574

    Modulation of P53 for the treatment of cancer

    The Regents of the University of California · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11497781

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

    CG ONCOLOGY, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11498963

    Anti-LILRB antibodies and their use in detecting and treating cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11497770

    Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

    The Regents of the University of Colorado · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11484511

    Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer

    KOREA UNITED PHARM. INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11484581

    Method to create personalized canine cancer vaccines

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11479611

    HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

    China Medical University Hospital · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11479613

    Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins

    AUTOLUS LIMITED · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11479614

    Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors

    AUTOLUS LIMITED · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11478500

    Anticancer compositions and methods for making and using them

    The Regents of the University of California · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11479769

    Technique for treating cancer using structurally-reinforced S-TuD

    GeneDesign, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11479774

    Methods of treating cancer harboring hemizygous loss of TP53

    The Board of Regents of the University of Texas System · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11472812

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11471460

    Autophagy modulators for use in treating cancer

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11471491

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11464784

    Inhibition of aminocylase 3 (AA3) in the treatment of cancer

    The Regents of the University of California · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. CA 3215723

    PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE

    ADVANCED ACCELERATOR APPLICATIONS [FR] · Granted Thu Oct 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11459381

    Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11458212

    Molecular imaging of cancer cells in vivo

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11458127

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11458126

    DHODH inhibitor for use in treating hematologic cancers

    PTC THERAPEUTICS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11458171

    Engineering stem cells for cancer therapy

    China Medical University · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11453719

    Compositions and methods for treating cancer with anti-ROR1 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11453640

    Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

    Northwestern University · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11446302

    Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

    The Board of Regents of the University of Texas System · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11446332

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11447563

    Tumor selective macropinocytosis-dependent rapidly internalizing antibodies

    The Regents of the University of California · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11447830

    Gene signatures to predict drug response in cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11439635

    B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

    Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11439669

    C. novyi for the treatment of solid tumors in humans

    Biomed Valley Discoveries, Inc. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11440939

    Anticancer peptides

    IDP DISCOVERY PHARMA, S.L. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11439709

    Phospholipid ether analogs as cancer-targeting drug vehicles

    CELLECTAR BIOSCIENCES, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11433097

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11433143

    Nano-enabled immunotherapy in cancer

    The Regents of the University of California · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11432547

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11433137

    Compounds for treating cancer

    BicycleRD Limited · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11434300

    Methods and antibody compositions for tumor treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11427816

    Cancer treatment through RLIP76 partial depletion

    The Board of Regents of the University of Texas System · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11426385

    Methods of improving cancer chemotherapy

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11427646

    Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

    B CELL DESIGN · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.